European Heart Journal · 2021 · 46 citations · 19 references
PharmacyCardiologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyInterventional CardiologyCardiovascular Drug SafetyCoronary Artery DiseaseDiabetes ManagementDiabetes PharmacotherapyDyslipidemia ManagementAcute Adverse EventsCoronary Artery Disease PharmacotherapyStent Thrombosis Prevention
AIM: Patients with diabetes mellitus are at high risk of adverse events after percutaneous revascularization, with no differences in outcomes between most contemporary drug-eluting stents. The Cre8 EVO stent releases a formulation of sirolimus with an amphiphilic carrier from laser-dug wells, and has shown clinical benefits in diabetes. We aimed to compare Cre8 EVO stents to Resolute Onyx stents (a contemporary polymer-based zotarolimus-eluting stent) in patients with diabetes. METHODS AND RESULTS: We did an investigator-initiated, randomized, controlled, assessor-blinded trial at 23 sites in Spain. Eligible patients had diabetes and required percutaneous coronary intervention. A total of 1175 patients were randomly assigned (1:1) to receive Cre8 EVO or Resolute Onyx stents. The primary endpoint was target-lesion failure, defined as a composite of cardiac death, target-vessel myocardial infarction, and clinically indicated target-lesion revascularization at 1-year follow-up. The trial had a non-inferiority design with a 4% margin for the primary endpoint. A superiority analysis was planned if non-inferiority was confirmed. There were 106 primary events, 42 (7.2%) in the Cre8 EVO group and 64 (10.9%) in the Resolute Onyx group [hazard ratio (HR): 0.65, 95% confidence interval (CI): 0.44-0.96; Pnon-inferiority < 0.001; Psuperiority = 0.030]. Among the secondary endpoints, Cre8 EVO stents had significantly lower rate than Resolute Onyx stents of target-vessel failure (7.5% vs. 11.1%, HR: 0.67, 95% CI: 0.46-0.99; P = 0.042). Probable or definite stent thrombosis and all-cause death were not significantly different between groups. CONCLUSION: In patients with diabetes, Cre8 EVO stents were non-inferior to Resolute Onyx stents with regard to target-lesion failure composite outcome. An exploratory analysis for superiority at 1 year suggests that the Cre8 EVO stents might be superior to Resolute Onyx stents with regard to the same outcome. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT03321032.
19
Pouya Saeedi, Inga Petersohn, Belma Malanda et al. · Diabetes Research and Clinical Practice · 2019 · 10.5K citations
Gerhard Hindricks, Tatjana Potpara, Nikolaos Dagres et al. · European Heart Journal · 2020 · 9.9K citations · Full text
2018 ESC/EACTS Guidelines on myocardial revascularization
Franz‐Josef Neumann, Miguel Sousa‐Uva, Anders Ahlsson et al. · European Heart Journal · 2018 · 7.1K citations · Full text
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Frank L.J. Visseren, François Mach, Yvo M. Smulders et al. · European Heart Journal · 2021 · 6.3K citations · Full text
Third Universal Definition of Myocardial Infarction
Kristian Thygesen, Joseph S. Alpert, Allan S. Jaffe et al. · Circulation · 2012 · 3K citations · Full text